Towards clinical development of a Pfs48/45-based transmission blocking malaria vaccine

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Towards clinical development of a Pfs48/45-based transmission blocking malaria vaccine. / Theisen, Michael; Jore, Matthijs M; Sauerwein, Robert.

In: Expert Review of Vaccines, Vol. 16, No. 4, 2017, p. 329-336.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Theisen, M, Jore, MM & Sauerwein, R 2017, 'Towards clinical development of a Pfs48/45-based transmission blocking malaria vaccine', Expert Review of Vaccines, vol. 16, no. 4, pp. 329-336. https://doi.org/10.1080/14760584.2017.1276833

APA

Theisen, M., Jore, M. M., & Sauerwein, R. (2017). Towards clinical development of a Pfs48/45-based transmission blocking malaria vaccine. Expert Review of Vaccines, 16(4), 329-336. https://doi.org/10.1080/14760584.2017.1276833

Vancouver

Theisen M, Jore MM, Sauerwein R. Towards clinical development of a Pfs48/45-based transmission blocking malaria vaccine. Expert Review of Vaccines. 2017;16(4):329-336. https://doi.org/10.1080/14760584.2017.1276833

Author

Theisen, Michael ; Jore, Matthijs M ; Sauerwein, Robert. / Towards clinical development of a Pfs48/45-based transmission blocking malaria vaccine. In: Expert Review of Vaccines. 2017 ; Vol. 16, No. 4. pp. 329-336.

Bibtex

@article{d8ea9cd4fe6c458ea45c06d5046488b7,
title = "Towards clinical development of a Pfs48/45-based transmission blocking malaria vaccine",
abstract = "Introduction: Malaria is a devastating vector-borne disease caused by the Plasmodium parasite, resulting in almost 0.5 million casualties per year. The parasite has a complex life-cycle that includes asexual replication in human red blood cells, causing symptomatic malaria, and sexual stages which are essential for the transmission to the mosquito vector. A vaccine targeting the sexual stages of the parasite and thus blocking transmission will be instrumental for the eradication of malaria. One of the leading transmission blocking vaccine candidates is the sexual stage antigen Pfs48/45.Areas covered: PubMed was searched to review the progress and future prospects for clinical development of a Pfs48/45-based subunit vaccine. We will focus on biological function, naturally acquired immunity, functional activity of specific antibodies, sequence diversity, production of recombinant protein and preclinical studies.Expert commentary: Pfs48/45 is one of the lead-candidates for a transmission blocking vaccine and should be further explored in clinical trials.",
keywords = "Journal Article",
author = "Michael Theisen and Jore, {Matthijs M} and Robert Sauerwein",
year = "2017",
doi = "10.1080/14760584.2017.1276833",
language = "English",
volume = "16",
pages = "329--336",
journal = "Expert Review of Vaccines",
issn = "1476-0584",
publisher = "Taylor & Francis",
number = "4",

}

RIS

TY - JOUR

T1 - Towards clinical development of a Pfs48/45-based transmission blocking malaria vaccine

AU - Theisen, Michael

AU - Jore, Matthijs M

AU - Sauerwein, Robert

PY - 2017

Y1 - 2017

N2 - Introduction: Malaria is a devastating vector-borne disease caused by the Plasmodium parasite, resulting in almost 0.5 million casualties per year. The parasite has a complex life-cycle that includes asexual replication in human red blood cells, causing symptomatic malaria, and sexual stages which are essential for the transmission to the mosquito vector. A vaccine targeting the sexual stages of the parasite and thus blocking transmission will be instrumental for the eradication of malaria. One of the leading transmission blocking vaccine candidates is the sexual stage antigen Pfs48/45.Areas covered: PubMed was searched to review the progress and future prospects for clinical development of a Pfs48/45-based subunit vaccine. We will focus on biological function, naturally acquired immunity, functional activity of specific antibodies, sequence diversity, production of recombinant protein and preclinical studies.Expert commentary: Pfs48/45 is one of the lead-candidates for a transmission blocking vaccine and should be further explored in clinical trials.

AB - Introduction: Malaria is a devastating vector-borne disease caused by the Plasmodium parasite, resulting in almost 0.5 million casualties per year. The parasite has a complex life-cycle that includes asexual replication in human red blood cells, causing symptomatic malaria, and sexual stages which are essential for the transmission to the mosquito vector. A vaccine targeting the sexual stages of the parasite and thus blocking transmission will be instrumental for the eradication of malaria. One of the leading transmission blocking vaccine candidates is the sexual stage antigen Pfs48/45.Areas covered: PubMed was searched to review the progress and future prospects for clinical development of a Pfs48/45-based subunit vaccine. We will focus on biological function, naturally acquired immunity, functional activity of specific antibodies, sequence diversity, production of recombinant protein and preclinical studies.Expert commentary: Pfs48/45 is one of the lead-candidates for a transmission blocking vaccine and should be further explored in clinical trials.

KW - Journal Article

U2 - 10.1080/14760584.2017.1276833

DO - 10.1080/14760584.2017.1276833

M3 - Journal article

C2 - 28043178

VL - 16

SP - 329

EP - 336

JO - Expert Review of Vaccines

JF - Expert Review of Vaccines

SN - 1476-0584

IS - 4

ER -

ID: 174234581